Covington-based Bexion Pharmaceuticals has been awarded a Small Business Innovation Research (SBIR) "Bridge Award" by the National Cancer Institute (NCI). The award of $2.9 million over three years will help Bexion further its clinical development of BXQ-350, a drug intended for use as an anti-cancer agent.
Read more.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.